Complement 3 Glomerulopathy (C3G) Market Analysis Report 2026-2036 Complement 3 Glomerulopathy Market Forecast To Reach Approximately $1 Billion By 2036 As Targeted Therapies Transform C3G Treatment
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Complement 3 Glomerulopathy - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of the C3G market, patient population, treatment landscape, competitive environment, and commercial opportunities across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
The Complement 3 Glomerulopathy market is projected to reach approximately USD 1 billion by 2036, expanding at an estimated compound annual growth rate of 28% from 2026 to 2036. Growth is expected to be driven by improving diagnostic capabilities, greater awareness of complement-mediated kidney diseases, increasing use of genetic and complement testing, and the introduction of targeted therapies.
Complement 3 Glomerulopathy Disease and Epidemiology Insights
C3G is associated with several glomerulonephritis patterns, including membranoproliferative, mesangial proliferative, diffuse endocapillary proliferative, and crescentic presentations. The disease is classified into Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN), based primarily on kidney biopsy findings. DDD frequently presents earlier, often during adolescence.
C3G has a progressive clinical course and a substantial risk of recurrence. Approximately 30% to 50% of patients may develop End-stage Kidney Disease within 10 years of diagnosis, underscoring the need for earlier detection and effective long-term treatment.
- The diagnosed prevalent C3G population in the 7MM was approximately 6,000 in 2025. The United States accounted for around 3,500 diagnosed prevalent cases in 2025. Adults represented approximately 90% of diagnosed US cases, while pediatric patients accounted for about 10%. The diagnosed population is forecast to increase through 2036 as access to renal biopsy evaluation, genetic testing, and complement assays improves.
Complement 3 Glomerulopathy Treatment Landscape
Historically, C3G management relied heavily on supportive care and off-label therapies, including corticosteroids, immunosuppressants, Renin-Angiotensin-Aldosterone System inhibitors, calcineurin inhibitors, eculizumab, and rituximab. Renoprotective strategies remain important for controlling hypertension, proteinuria, and other contributors to kidney disease progression.
The treatment landscape changed significantly in 2025 with the introduction of targeted complement inhibitors. In March 2025, the US Food and Drug Administration approved Novartis' iptacopan (FABHALTA) for adults with C3G. Iptacopan is an oral Factor B inhibitor targeting the alternative complement pathway. In April 2025, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending authorization for iptacopan in adults with C3G.
In July 2025, the FDA approved pegcetacoplan (EMPAVELI) for patients aged 12 years and older with C3G or primary Immune-Complex Membranoproliferative Glomerulonephritis. Pegcetacoplan targets C3 and provides proximal complement inhibition. In January 2026, the European Commission approved ASPAVELI for adults and adolescents aged 12 to 17 years with C3G or primary IC-MPGN, in combination with a Renin-Angiotensin System inhibitor unless that treatment is contraindicated or not tolerated.
Complement inhibitors are associated with clinically important infection risks, particularly infections caused by encapsulated bacteria. Vaccination, risk evaluation, and ongoing monitoring are therefore central to treatment initiation and patient management.
C3G Pipeline and Competitive Landscape
The emerging Complement 3 Glomerulopathy pipeline includes therapies targeting multiple points in the complement cascade. Leading investigational approaches include dual complement inhibition, MASP-3 inhibition, RNA interference, monoclonal antibodies, bifunctional biologics, and small-molecule therapies.
- KP104 - Kira Pharmaceuticals: A bifunctional biologic designed to inhibit the alternative and terminal complement pathways. The candidate is progressing through Phase II development across several complement-mediated diseases, including C3G. Zaltenibart (OMS906) - Omeros Corporation/Novo Nordisk: An investigational monoclonal antibody targeting MASP-3. Further late-stage development in C3G is anticipated subject to clinical results. ARO-C3 - Arrowhead Pharmaceuticals: An RNA interference therapeutic targeting complement C3.
Key companies shaping the C3G competitive landscape include Novartis, Apellis Pharmaceuticals, Sobi, Kira Pharmaceuticals, Novo Nordisk, Omeros Corporation, and Arrowhead Pharmaceuticals. Pipeline launches are expected to increase competition and broaden treatment options during the 2026-2036 forecast period.
Complement 3 Glomerulopathy Market Drivers and Unmet Needs
- Advances in complement biology are supporting the development of more selective treatments. Broader use of renal biopsy interpretation, complement assays, and genetic testing is improving diagnostic accuracy. Growing disease awareness and retrospective studies suggest C3G may be more prevalent than previously estimated. High rates of progression to kidney failure continue to create demand for treatments that preserve long-term renal function. Major unmet needs include earlier biomarkers, reduced misdiagnosis, pediatric and transplant treatment evidence, and long-term real-world efficacy and safety data.
The United States represents the largest C3G market, accounting for approximately 70% of the 7MM market. Future therapy uptake will depend on comparative efficacy, safety, route and frequency of administration, pricing, reimbursement, patient eligibility, order of entry, and the ability to demonstrate sustained kidney protection.
Market Access, Pricing, and Reimbursement
The report evaluates country-specific market access, reimbursement pathways, affordability programs, out-of-pocket costs, and potential payment models for high-cost C3G therapies. It also reviews pricing benchmarks and analogue selection for emerging products. Based on a listed 2023 wholesale acquisition cost of USD 4,535.96 per dose and twice-weekly administration, the estimated annual cost of EMPAVELI was approximately USD 500,469.
Eligible commercially insured patients may have access to manufacturer assistance programs. The FABHALTA Co-pay Plus program, for example, may reduce eligible patient out-of-pocket costs to as little as USD 0, subject to program requirements and an annual benefit limit of USD 20,000 per calendar year.
Report Coverage and Strategic Value
The C3G market report includes historical and forecast epidemiology from 2022 to 2036, treatment algorithms, marketed and pipeline drug profiles, therapy uptake forecasts, peak patient-share analysis, pricing trends, reimbursement insights, and country-level market projections. Epidemiology is segmented by diagnosed prevalence, disease type, age group, and treated cases.
The research also incorporates SWOT analysis, conjoint analysis, patient-journey assessment, and perspectives from nephrologists, medical and scientific experts, and other key opinion leaders across the 7MM. These insights help evaluate treatment preferences, access barriers, competitive positioning, and the commercial potential of emerging C3G therapies.
The report supports pharmaceutical companies, investors, healthcare organizations, and market-access teams in identifying growth opportunities, evaluating competitors, prioritizing development strategies, and preparing for changes in the Complement 3 Glomerulopathy treatment market through 2036.
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis Apellis Pharmaceuticals Sobi Kira Pharmaceuticals Novo Nordisk/Omeros Corporation Arrowhead Pharmaceuticals
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment